Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain u...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wiley
2026-04-01
|
| Serier: | Annals of Clinical and Translational Neurology |
| Fag: | |
| Online adgang: | https://doi.org/10.1002/acn3.70246 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|